title: Is active acid sphingomyelinase required for the antiproliferative response to rituximab?
authors: Frédérique
authors: F
authors: Sabourdy
authors: Janick
authors: J
authors: Selves
authors: Leonardo
authors: L
authors: Astudillo
authors: Camille
authors: C
authors: Laurent
authors: Pierre
authors: P
authors: Brousset
authors: Marie-Bernadette
authors: MB
authors: Delisle
authors: Nicole
authors: N
authors: Therville
authors: Nathalie
authors: N
authors: Andrieu-Abadie
authors: Bruno
authors: B
authors: Ségui
authors: Christian
authors: C
authors: Recher
authors: Thierry
authors: T
authors: Levade
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D049109:Cell Proliferation / Q000187:drug effects*; D003520:Cyclophosphamide / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy / Q000235:genetics; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D013108:Sphingomyelin Phosphodiesterase / Q000172:deficiency / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D017211:Treatment Failure; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D003520:Cyclophosphamide; C543066:SMPD1 protein, human; D013108:Sphingomyelin Phosphodiesterase; D011241:Prednisone